



Edition: BP 2025 (Ph. Eur. 11.6 update)

## Desmopressin Oral Lyophilisate

### [General Notices](#)

#### Action and use

Vasopressin analogue; treatment of diabetes insipidus.

### DEFINITION

Desmopressin Oral Lyophilisate contains Desmopressin with suitable [excipients](#).

The oral lyophilisate complies with the requirements stated under [Tablets](#) and with the following requirements.

#### Content of desmopressin, $C_{46}H_{64}N_{14}O_{12}S_2$

90.0 to 110.0% of the stated amount of the peptide.

### IDENTIFICATION

In the Assay, the principal peak in the chromatogram obtained with solution (1) corresponds to that in the chromatogram obtained with solution (2).

### TESTS

#### Related substances

Carry out the method for [liquid chromatography, Appendix III D](#), using the following solutions and the *normalisation procedure*.

- (1) Shake a quantity of the oral lyophilisate with 10 mL of a mixture of 50% of the buffer solution and 50% of [water](#) to produce a solution containing 0.0025% w/v of the peptide.
- (2) Dissolve the contents of a vial of [desmopressin impurity standard BPCRS](#) in 4 mL of a mixture of 50% of the buffer solution and 50% of [water](#).

#### CHROMATOGRAPHIC CONDITIONS

- (a) Use a stainless steel column (15 cm x 3.0 mm) packed with nitrile groups chemically bonded to porous silica particles (5 µm) (Zorbax-SB-CN is suitable).
- (b) Use gradient elution and the mobile phase described below.
- (c) Use a flow rate of 0.6 mL per minute.
- (d) Use a column temperature of 50°.
- (e) Use a detection wavelength of 220 nm.
- (f) Inject 200 µL of each solution.

#### Buffer solution

0.05 M ammonium acetate buffer solution, pH 4.6, if necessary adjusted with [acetic acid](#).

#### Mobile phase A

15 volumes of [acetonitrile](#), 35 volumes of [water](#) and 50 volumes of the Buffer solution.

#### Mobile phase B

15 volumes of [water](#), 40 volumes of [acetonitrile](#) and 45 volumes of the Buffer solution.

Time (Minutes)	Mobile phase A (% v/v)	Mobile phase B (% v/v)	Comment
0-16	100	0	isocratic
16-31	100→0	0→100	linear gradient
31-36	0	100	isocratic
36-37	0→100	100→0	linear gradient
37-41	100	0	re-equilibration

When the chromatograms are recorded under the prescribed conditions the retention time for the first peak: in solution (2) is about 9 minutes and about 11 minutes for desmopressin.

#### SYSTEM SUITABILITY

The test is not valid unless:

in the chromatogram obtained with solution (2), the [resolution](#) between the two principal peaks is at least 2.0;

the peak due to desmopressin is clearly separated from any peaks due to [excipients](#) stated on the label.

#### LIMITS

In the chromatogram obtained with solution (1):

the area of any [secondary peak](#) is not more than 2.0%;

the total area of any such peaks is not more than 4.0%.

Disregard any peak due to the solvent, any [excipients](#) stated on the label and any peak with an area less than 0.05%.

## ASSAY

Carry out the method for [liquid chromatography, Appendix III D](#), using the following solutions.

- (1) Shake a suitable quantity of the oral lyophilisate with 10 mL of a mixture of 50% of the Buffer solution and 50% of [water](#), to give a final concentration of 0.0025% w/v of the peptide.
- (2) Dissolve the contents of a vial of [desmopressin BPCRS](#) in a mixture of 50% of the Buffer solution and 50% of [water](#), to give a final concentration of 0.0025% w/v of the peptide.
- (3) Dissolve the contents of a vial of [desmopressin impurity standard BPCRS](#) in 4 mL of a mixture of 50% of the Buffer solution and 50% of [water](#).

#### CHROMATOGRAPHIC CONDITIONS

- (a) Use a stainless steel column (15 cm x 3.0 mm) packed with nitrile groups chemically bonded to porous silica particles (5 µm) (Zorbax-SB-CN is suitable).
- (b) Use isocratic elution and the mobile phase described below.
- (c) Use a flow rate of 0.6 mL per minute.
- (d) Use a column temperature of 50°.
- (e) Use a detection wavelength of 220 nm.
- (f) Inject 200 µL of each solution.

Carry out isocratic elution for at least 16 minutes for each run.

#### MOBILE PHASE

**Buffer solution** 0.05M ammonium acetate buffer solution, pH 4.6, 15 volumes of [acetonitrile](#), 35 volumes of [water](#) and 50 volumes of the Buffer solution.

#### SYSTEM SUITABILITY

The test is not valid unless:

in the chromatogram obtained with solution (3), the [resolution](#) between the two principal peaks and desmopressin is at least 2.0;

the peak due to desmopressin is clearly separated from any peaks due to [excipients](#) stated on the label.

#### DETERMINATION OF CONTENT

Calculate the content of  $C_{46}H_{64}N_{14}O_{12}S_2$  in each tablet from the chromatograms obtained and from the declared content of  $C_{46}H_{64}N_{14}O_{12}S_2$  in [desmopressin BPCRS](#).

## STORAGE

Desmopressin Oral Lyophilisate should be protected from light and moisture.

## IMPURITIES

The impurities limited by the requirements of this monograph include those listed under Desmopressin.